The “most favored nation” (MFN) drug pricing deal AstraZeneca recently signed with the Trump administration won’t affect the ...

Caplyta, the crown jewel of Johnson & Johnson's $14.6 billion buyout of Intra-Cellular Therapies, won the FDA’s blessing to ...

Incyte has expanded its support for projects tackling unmet needs to cover hidradenitis suppurativa (HS) patients, tightening ...

Cencora plans to spend $1 billion over the next 5 years to expand its operations in the U.S., including opening a second ...

Even with Inflation Reduction Act (IRA)-related pressure looming for its top product, Teva Pharmaceuticals is continuing to ...

Some eight months into the launch of Onapgo, the Parkinson’s disease infusion pump Supernus Pharmaceuticals spent years fighting to get across the FDA finish line, the drugmaker is discovering that ...

Less than three months into his tenure, Novo Nordisk’s new CEO has undeniably left his mark on the company, launching a ...

In just its fifth full quarter on the market, the world’s first treatment for metabolic dysfunction-associated ...

The Trump administration has spent much of this year working to coerce drugmakers into lowering their prices in the U.S. | ...

Katie Swicegood Fulp is a bit of a late arrival to the world of pharma marketing. | In a Q&A for Fierce Pharma Marketing’s ...

Eli Lilly is going for gold at the Milano Cortina 2026 Olympic and Paralympic Winter Games. | Eli Lilly is going for gold at ...

The latest investment brings the British pharma’s total investment at the site in Qingdao to $886 million. AstraZeneca ...